- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/16 - Peri-condensed systems
Patent holdings for IPC class C07D 471/16
Total number of patents in this class: 420
10-year publication summary
|
19
|
25
|
22
|
32
|
41
|
30
|
31
|
34
|
41
|
24
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Intra-Cellular Therapies, Inc. | 410 |
90 |
| Merck Patent GmbH | 5820 |
29 |
| Genentech, Inc. | 3988 |
10 |
| Merck Sharp & Dohme LLC | 3750 |
8 |
| Glaxo Group Limited | 4104 |
7 |
| Bristol-myers Squibb Company | 4867 |
6 |
| Merck Sharp & Dohme Corp. | 2191 |
6 |
| Universal Display Corporation | 1930 |
6 |
| UTi Limited Partnership | 452 |
6 |
| Glaxosmithkline Intellectual Property Development Limited | 764 |
5 |
| Abbvie Inc. | 1799 |
5 |
| BeiGene Switzerland GmbH | 162 |
5 |
| Samsung Display Co., Ltd. | 35100 |
4 |
| FUJIFILM Corporation | 29506 |
4 |
| Takeda Pharmaceutical Company Limited | 2707 |
4 |
| University of Florida Research Foundation, Inc. | 4044 |
4 |
| Actelion Pharmaceuticals Ltd | 531 |
4 |
| Teva Pharmaceuticals International GmbH | 332 |
4 |
| Novartis AG | 10726 |
3 |
| The Regents of the University of Michigan | 4733 |
3 |
| Other owners | 207 |